
TITAN PHARMACEUTICALS INC
Form 8-K
March 09, 2015
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 9, 2015
Bute of Report (Bute of Burnest Event Reported). Waren 7, 2015
Titan Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
0-27436 94-3171940
(Commission File Number) (IRS Employer Identification No.)

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080

(Address of principal executive offices and zip code)

650-244-4990



Item 7.01. Regulation FD Disclosure.

On March 9, 2015, Titan Pharmaceuticals, Inc. will present at a conference and post on its website a corporate presentation and fact sheet, copies of which are attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated herein by reference.

The foregoing information, including the presentation and fact sheet attached hereto as Exhibits, is being furnished pursuant to Item 7.01 of this Current Report and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.

Item 9.01. Financial Statement and Exhibits.

(d) Exhibits.

Exhibit No. Description

- 99.1 Corporate Presentation
- 99.2 Corporate Fact Sheet

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TITAN PHARMACEUTICALS, INC.

By: /s/ Sunil Bhonsle Name: Sunil Bhonsle Title: President

Dated: March 9, 2015